|
Antiretroviral therapy prior to nevirapine-containing regimen |
||||||||
| PATIENT |
AGE at 1st regimen |
Mono-therapy |
Dual-therapy |
Cumulative duration |
HAART |
Cumulative duration |
CD4% |
Viral load cop/ml |
|
|
||||||||
| months |
NRTI |
NRTI |
NRTI |
PI |
PI |
0–12 months |
0–12 months |
|
| D4T-3TC- |
AMP(36 m)+ |
|||||||
| 1 |
119 |
NO |
ZDV-DDI |
27 |
AMP+RIT |
RIT (6 m) |
33–41 |
50–50 |
| 2 |
39 |
NO |
ZDV-DDI |
36 |
D4T-3TC-AMP |
AMP(48 m) |
32–30 |
50–50 |
| 3 |
65 |
NO |
NO |
0 |
ZDV-DDI-RIT |
RIT(32 m) |
29–34 |
50–50 |
| 4 |
14 |
ZDV |
ZDV-DDI |
19+21 |
D4T-3TC-NFV |
NFV(56 m) |
42–44 |
50–50 |
| 5 |
92 |
NO |
NO |
0 |
ZDV-ABC-IND |
IND(28 m) |
34–30 |
50–50 |
| 6 |
9 |
ZDV/DDI |
NO |
109 |
ZDV-DDI-IND |
IND(60 m) |
32–27 |
50–10325 |
| 7 |
6 |
ZDV |
NO |
92 |
ZDV-3TC-IND |
IND(52 m) |
31–34 |
50–50 |
| 33%(29,42) |
||||||||
| median |
53 m (6,119) |
52 m (0,109) |
130 m (99,177) |
47 m (28,60) |
37%(27,44) |
50 |
||
|
NRTI: nucleoside reverse transcriptase inhibitor, ZDV: zidovudine, DDI: dianosine, D4T: stavudine, 3TC: lamivudine; PI: protease inhibitor, AMP: amprenavir, RIT: ritonavir, NFV: nefinavir, IND: indinavir; m: months; cop/ml: copies/ml (HIV-RNA, liner range: 50–500.000 cop/ml) | ||||||||
Gonzalez-Tome et al. BMC Infectious Diseases 2008 8:144 doi:10.1186/1471-2334-8-144 |
||||||||